Lung cancer survival signal
Small cell lung cancer (SCLC) represents up to 25 percent of lung cancer cell deaths and is associated with early metastasis and poor patient survival. Thus, SCLC is in need of better therapeutics and more efficient targeted treatments. Jonathan Lehman, MD, PhD, Pierre Massion, MD,and colleagues have demonstrated that somatostatin receptor 2 (SSTR2), considered to be a cell growth inhibitor, […]
Continue reading »